Review Papers Claim by Claim

High-level claims and supporting evidence (paper)

• PAD4 and HDAC2 physically interact — shown by affinity purification of FLAG‑PAD4 recovering HDAC2 and p53, reciprocal GST pull‑downs, and endogenous co‑IP (Li et al., Oncogene 2010) Li et al., Fig.1 biochemical interactions
• PAD4 & HDAC2 co-occupy p53 target promoters and dissociate after DNA damage — re-ChIP and ChIP-qPCR at p21 (two PBS sites), GADD45, PUMA show both enzymes bound before DNA damage and reduced occupancy after doxorubicin with reciprocal changes in histone marks (H3Cit↓, H3R17Me↑, H3K9/14Ac↑) Li et al., ChIP and Re-ChIP at p21/GADD45/PUMA
• Functional modulation: inhibitors and knockdown — siRNA of PAD4 or HDAC2 increased p21 protein; combined small‑molecule inhibitors Cl‑amidine (PAD4) and SAHA (HDAC) additively increased p53-target transcripts and inhibited U2OS cell growth in a p53-dependent manner (U2OS vs U2OS/p53-shRNA) Li et al., inhibitor and siRNA functional assays

Critical evaluation — strengths

• Coherent multi-level approach: in vitro biochemistry (GST pulls, enzymatic assays), ChIP/re-ChIP, loss/gain perturbations and pharmacology converge on the same model (PAD4+HDAC2 corepression of p53 targets) Li et al., integrative evidence
• Mechanistic insight: mapping of PAD4 IgL domains as necessary for HDAC2 interaction and p53 C-terminus involvement refines domain-level model for complex assembly (Figure 2) Li et al., domain mapping

Critical evaluation — limitations & blindspots

1. Cell-line only, limited generality: all mechanistic and functional data come from human cancer cell lines (MCF‑7, U2OS, 293T), so in vivo relevance, tissue specificity and effects in primary cells remain untested in this work Li et al., model systems
2. Quantitative depth and genome-wide scope missing: ChIP-qPCR at selected promoters is informative but lacks ChIP‑seq or global profiling to define genomic breadth of PAD4–HDAC2 co-occupancy or off-target effects; the paper uses % input and small n for ChIP replicates but does not provide raw datasets for reanalysis Li et al., ChIP scope
3. Inhibitor specificity & doses: SAHA is a pan-HDAC inhibitor; Cl‑amidine is a PAD inhibitor that can have off-targets at high concentrations used (200 μM); thus additive effects should be interpreted cautiously until isoform-selective tools and dose–response curves in primary models are applied Li et al., inhibitor use and caveats
4. Stoichiometry / complex architecture uncertain: copurified HDAC2 estimated ~1% with FLAG‑PAD4 implying sub-stoichiometric or transient interaction; structural/biophysical characterization of complex (and whether other scaffolds mediate recruitment) is lacking Li et al., interaction stoichiometry note

Where the conclusions are robust, and where further data would change them

• Robust: biochemical interaction (pulldown/co-IP) and promoter co‑occupancy at chosen p53-target promoters are well supported by the described experiments Li et al., core molecular evidence
• Sensitive: the therapeutic angle (combination PAD4 + HDAC inhibition) is promising but preliminary — additive growth inhibition in U2OS is supportive but requires isoform-selective inhibitors, dose–response, toxicity profiling, and testing across p53-wildtype versus mutant tumor models and in vivo xenografts before translational claims can be sustained Li et al., functional therapy data

Practical reproducibility checklist (what to report if repeating)

1. Exact antibody clones and lot numbers for ChIP (H3Cit, H3R17Me, H3K9/14Ac, PAD4, HDAC2) and validation blots.
2. Number of biological replicate ChIPs, raw % input values and Ct values, primer sequences (paper says "available on request") and full qPCR efficiencies.
3. Full details on inhibitor preparation, stock solvents, treatment durations, dose ranges and cell viability controls for Cl‑amidine and SAHA.
4. Mass spectrometry evidence for complex partners if available (authors mention MS-based SHARP detection but did not show raw spectra in the text).

Concise suggested experiments to strengthen/extend the paper

1. ChIP‑seq for PAD4 and HDAC2 (±doxorubicin) to define genomic co‑occupancy and whether the effect is p53-centric or broader.
2. Use of HDAC2-selective perturbation (isoform-selective degrader or CRISPRi) and PAD4-specific chemical probes with matched dose–response and orthogonal target engagement assays; include primary cells.
3. Co-immunoprecipitation mass spectrometry (IP‑MS) to define full complex composition and stoichiometry; crosslinking MS to map contact interfaces.
4. In vivo xenograft or genetically engineered mouse tumor models (p53 WT vs mutant) to test combined PAD4 + HDAC2 inhibition efficacy and toxicity.

Bottom line (conclusion & confidence)

The paper presents coherent biochemical and chromatin-level evidence that PAD4 and HDAC2 interact and co‑occupy p53 target promoters, modulating histone citrullination, arginine methylation and lysine acetylation during DNA damage response, with functional consequences on p53-target gene induction and cancer cell growth in vitro. Confidence in the molecular interactions and promoter dynamics is moderate; confidence in therapeutic translation is low–moderate without selective tools and in vivo validation (see supporting citation) Li et al., overall conclusions